Gritstone Bio (Gritstone Bio) Debt-to-Revenue : 526.95 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Gritstone Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.81 Mil. Gritstone Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $96.47 Mil. Gritstone Bio's annualized Revenue for the quarter that ended in Mar. 2024 was $0.20 Mil. Gritstone Bio's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 526.95.

Gritstone Bio Debt-to-Revenue Historical Data

The historical data trend for Gritstone Bio's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio Debt-to-Revenue Chart

Gritstone Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

5.38

7.25

0.57

4.35

78.72

Gritstone Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															22.50	59.62	66.00	903.23	526.95

Competitive Comparison of Gritstone Bio's Debt-to-Revenue

For the Biotechnology subindustry, Gritstone Bio's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gritstone Bio's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gritstone Bio's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's Debt-to-Revenue falls into.

Gritstone Bio Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Gritstone Bio's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6.904	+	97.871)	/	1.331
	=	78.72

Gritstone Bio's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6.811	+	96.471)	/	0.196
	=	526.95

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Gritstone Bio Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gritstone Bio (Gritstone Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

2JQ:Germany 2JQ:Germany

Address

5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608

Website

https://gritstonebio.com

Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.

Executives

Lawrence Corey	director	C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi	director	C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher	director	C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes	director	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Vassiliki Economides	officer: See Remarks	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Erin Jones	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
James Cho	officer: Chief Accounting Officer	C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rahsaan Thompson	officer: EVP and General Counsel	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Vijay Yabannavar	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Nicholas Simon	director	101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142